Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement


DX-88 (Ecallantide) for the Reduction of Blood Loss Associated With Cardiopulmonary Bypass: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study in Patients Undergoing Primary Coronary Artery Bypass Grafting, Single Valve Repair or Single Valve Replacement




The purpose of this study is to evaluate two different dose regimens of ecallantide to determine whether either or both dose regimens reduce blood loss, measured by chest tube drainage, compared to placebo during cardiopulmonary bypass surgery.

Study Status: Terminated


Condition Intervention Phase
Blood Loss, Surgical Drug: ecallantide
Drug: placebo
Phase 2

Verified by Cubist Pharmaceuticals September, 2008

Sponsored by: Cubist Pharmaceuticals
Information provided by: Cubist Pharmaceuticals identifier: NCT00448864

Study Type: Interventional

Study Design: Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States

Andrew L Sternlicht, MD., Study Director

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site